2025 AHA/ACC hypertensierichtlijn: preventie, detectie en management
De nieuwe 2025 AHA/ACC hypertensierichtlijn verlaagt de definitiedrempel naar 130/80 mmHg (convergentie met ESC 2024), benadrukt thuisbloeddrukmeting, en integreert GLP-1-agonisten en SGLT2-remmers bij hypertensie met metabole comorbiditeiten.
Abstract (original)
AIM: The "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults" retires and replaces the "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults." METHODS: A comprehensive literature search was conducted from December 2023 to June 2024 to identify clinical studies, reviews, and other evidence performed on human subjects that were published since February 2015 in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to create a living, working document updating current knowledge in the field of high blood pressure aimed at all practicing primary care and specialty clinicians who manage patients with hypertension.
Dit artikel is een samenvatting van een publicatie in Circulation. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.1161/CIR.0000000000001356
